Autres langues Active Biotech AB London S.E.

Actions

Temps réel estimé Cboe Europe 17:25:00 01/10/2026			Varia. 5j.	Varia. 1 janv.
3,825 ^SEK	-40,71%		+18,15%	+41,78%

30/09	Active Biotech obtient un brevet japonais pour le laquinimod	FW
30/09	Active Biotech obtient un brevet pour le laquinimod au Japon	FW

30/09	Analyst recommendations: Apple, Walt Disney, Nvidia, Tesla, Fair Isaac…
30/09	Active Biotech Strengthens Global Patent Protection for Laquinimod with Patent Grant in Japan
20/08	Active Biotech AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026
20/08	Active Biotech (Q2 Review): Record-Deals in Myelofibrosis in 2026
20/08	Active Biotech Interim Report Q2 2026
18/08	Active Biotech Collaborates with US Medical Institution to Advance Myelofibrosis Treatment Development
18/08	Active Biotech expands US collaboration to advance tasquinimod clinical development in myelofibrosis
24/07	Active Biotech Doses First Patient in Amended Ho172 Clinical Study of Tasquinimod in Myelofibrosis
24/07	Active Biotech Doses First Patient in Amended Tasquinimod Myelofibrosis Trial
24/07	First patient dosed in the amended HO172 clinical study of tasquinimod in myelofibrosis
30/06	Number of shares and votes in Active Biotech
07/06	Certain Shares of Active Biotech AB are subject to a Lock-Up Agreement Ending on 7-JUN-2026.
01/04	Active Biotech AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2025